Stem cell treatment for acute myocardial infarction.

Stem cell treatment for acute myocardial infarction. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Stem cell treatment for acute myocardial infarction. Abstract Text:

BACKGROUND: Stem cell therapy offers a promising approach to the regeneration of damaged vascular and cardiac tissue after myocardial infarction (MI). This has resulted in multiple randomised controlled trials (RCTs) worldwide. OBJECTIVES: To critically evaluate evidence from RCTs on the effectiveness of adult bone marrow-derived stem cells (BMSC) to treat acute MI. SEARCH STRATEGY: MEDLINE (1950 to August 2007), EMBASE (1974 to August 2007), The Cochrane Library (Issue 3 2007), and CINAHL (1982 to August 2007) were searched. In addition LILACS, KOREAMED, INMED, Current Controlled Trials Register, the UK National Research Register and other handsearching was undertaken to August 2007. SELECTION CRITERIA: RCTs comparing autologous stem/progenitor cells with no autologous stem/progenitor cells in patients diagnosed with acute myocardial infarction (AMI) were eligible. DATA COLLECTION AND ANALYSIS: Two reviewers independently screened all references, assessed trial quality and extracted data. Meta-analyses using a random-effects model were conducted and heterogeneity was explored using sub-group analyses. MAIN RESULTS: Thirteen RCTs (811 participants) were included. There were insufficient events on clinical outcomes like mortality to draw clear conclusions. Stem/progenitor cell treatment does not appear to be associated with an increase in adverse events but again the data do not allow clear conclusions. Left ventricular ejection fraction (LVEF) was the outcome with most results and there was marked heterogeneity between trials. There was however a consistent pattern indicating that BMSC treatment generally improves short-term LVEF, with similar trends for left ventricular end systolic and end diastolic volumes (LVESV and LVEDV), infarct size or cardiac wall motion. There was a positive correlation between cell dose infused and the effect on LVEF measured by magentic resonance imaging. AUTHORS' CONCLUSIONS: The results of this systematic review suggest that there is little evidence to assess the clinical effects of this treatment. Larger trials using optimal dosing and more reliable, patient-centred outcomes are required. Several trials are ongoing but is unclear whether these will overcome the limitations of the current evidence base.

Stem cell treatment for acute myocardial infarction. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Stem cell treatment for acute myocardial infarction. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cochrane database of systematic reviews (Online)

VOLUME:

Page Numbers: CD006536

Journal Abbreviation:

ISSN: 1469-493X

DAY: 8

MONTH: 10

YEAR: 2008

Stem cell treatment for acute myocardial infarction. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100909747

Stem cell treatment for acute myocardial infarction. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Stem cell treatment for acute myocardial infarction. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Stem cell treatment for acute myocardial infarction.

AFFILIATION: Stem Cell Research Department, NHS Blood and Transplant , John Radcliffe Hospital, Headington, Oxford, UK, OX3 9BQ.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cochrane Database Syst Rev

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Stem cell treatment for acute myocardial infarction Related Publications

• Binocular depth perception in small-angle strabismus.
• CORRESPONDENCE.
• Conjunctival fibrosis after filtration operations.
• Defects of ocular movement and fusion after head injury.
• Kerato-conjunctivitis sicca.
• Modification in surface diathermy operations.
• Rheumatism and uveitis.
• Science and ophthalmology.
• Stem cell treatment for acute myocardial infarction.
• Stereopsis and depth perception after treatment for convergent squint.
• The Evidence-Based Use of FFP and Cryoprecipitate for Abnormalities of Coagulation Tests and Clinical Coagulopathy.
• The aetiology and treatment of uveitis.
• The cornea in polarized light.
• The final results of squint operations, in which restoration of binocular single vision was not expected.
• The measurement and clinical significance of the Haidinger effect.
• Transmission of bactericidal radiation through glass.
• Use of random-dot sterograms in the clinical assessment of strabismic patients.
• Visual aids for the pathological eye; excluding contact lenses.